2 Forbes Road,

Woburn,

Massachusetts,

USA,

ZIP: 01801

Phone: 12125375898

Part of the industry defining Microbiome Movement, we're delighted to announce the 2nd Microbiome Movement – Gut-Brain Axis 2020, a forum dedicated to demonstrating disease causality of the gut-brain axis and bridging the translational gap between the human gut Microbiome and effective treatments.

As the microbiome revolution continues to impact translational research, there has been tremendous progress to better characterize the bi-directional communication between the CNS, ENS and gastrointestinal tract to help treat well-known brain disorders including ASD, Parkinson's, Alzheimer's, depression and many more.

Through data driven case studies showcasing the latest pre-clinical and clinical research across industry and academia, uncover the role of multiple metabolic and immune-mediated pathways that are being proven to show an effect in the cause and development of CNS disease, tap into a unique network of likeminded researchers and capitalize on this exciting therapeutic opportunity.


URL:
Brochure: https://go.evvnt.com/260258-2?pid=1052

Category: Conferences | Science, Health and Medicine

Prices:
Conference Only Rate: USD 2199.0,
Conference + 1 Workshop: USD 2699.0

Speakers: Nader Yaghoubi , President and CEO, Symbiotix Biotherapies, Sian Hemmings, Associate Professor, Department of Psychiatry, Stellenbosch University, Patrice Garnier, CEO, AMABiotics, David Donabedian, CEO, Axial Biotherapeutics, Chris Reyes, Co-Founder and Chief Scientific Officer, Bloom Science, Gil Sharon, Postdoctoral Scholar in Biology. Mazmanian Lab, California Institute of Technology, Felice Jacka, Professor, School of Medicine, Deakin University, Elaine Patterson, Senior Scientist, DuPont Nutrition and Health, Malu Tansey, Professor, Department of Physiology, Emory University School of Medicine, Phil Strandwitz, Co-Founder and CEO, Holobiome, Derrick Macfabe, MD, Co-Founder and Director, Kilee Patchell-Evans Autism Research Group, Jane Foster, Associate Professor, Department of Psychiatry and Behavioural Neurosciences, McMaster University, Kuldip Dave, Director, Research Programs, Michael J. Fox Foundation, Christian Furlan Freguia, Director, Research, Synthetic Biologics, Valerie Taylor, Psychiatrist-in-Chief, Women's College Hospital, Natalia Palacios, Assistant Professor, Department of Public Health, UMass Lowell, John Lukens, Assistant Professor, University of Virginia School of Medicine, Kathleen Shannon, Detling Professor and Chair, Neurology, University of Wisconsin School of Medicine and Public Health